AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 662249 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea alone
Number of subjects: 0
Study 662249 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of urea and prostaglandin
Number of subjects: 0
Study 662249 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin and laminaria used in all groups
Number of subjects: 0
Study 31390035 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Outcomes Through Patient Empowerment (HOPE) - 9 telephone sessions with trained health care professionals using collaborative goal-setting and behavioral activation methods.
Number of subjects: 225
Study 31390035 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC) - notification of high-risk status.
Number of subjects: 225
Study 31390035 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Outcomes Through Patient Empowerment (HOPE) - 12 months follow-up.
Number of subjects: 225
Study 28152177 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure on specific acupoints (Tian-Zhu, Ju-Que, Yong-Quan, Bai-Hui, and Nei-Guan) three times a week for 8 weeks, 24 minutes each time
Number of subjects: 62
Study 28152177 — intervention group
Group type: COMPARATOR
Intervention: Massage at locations with no acupoints (10 mm from true points) three times a week for 8 weeks, 24 minutes each time
Number of subjects: 62
Study 26571987 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanolic leaf extracts of Ocimum sanctum (EtOS) 300 mg per day for 30 days
Number of subjects: 100
Study 26571987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 26571987 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanolic leaf extracts of Ocimum sanctum (EtOS)
Number of subjects: 100
Study 24083543 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 week exercise and counseling program (3 hours + 30 minutes per week of supervised and structured aerobic training at moderate to high intensity 70‐80%, strength exercises using hand weights, relaxation exercise, individual health counseling sessions with a self-directed home walk program)
Number of subjects: 70
Study 24083543 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70
Study 22145768 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based treatment group
Number of subjects: 53
Study 22145768 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face group
Number of subjects: 53
Study 22145768 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53
Study 19487510 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar eversion and anterior tibial translation
Number of subjects: 37
Study 19487510 — intervention group
Group type: COMPARATOR
Intervention: Patellar subluxation and no tibial translation
Number of subjects: 37
Study 17292768 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 224
Study 17292768 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 224
Study 17292768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 17292768 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin vs Clarithromycin
Number of subjects: 224
Study 15750254 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential hypertension patients
Number of subjects: 115
Study 15750254 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 115
Study 11281559 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU/day of salmon calcitonin subcutaneously for the first 6 months posttransplant
Number of subjects: 63
Study 11281559 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 63
Study 11281559 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63
Study 9153604 — intervention group
Group type: EXPERIMENTAL
Intervention: Early follow up group (additional information, advice, support, and further intervention offered at 7-10 days after injury)
Number of subjects: 1156
Study 9153604 — intervention group
Group type: COMPARATOR
Intervention: Standard service (control group)
Number of subjects: 1156
Study 7505423 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (34 mg/kg single morning dose)
Number of subjects: 0
Study 7505423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3112002 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT/LCT fat emulsion
Number of subjects: 20
Study 3112002 — intervention group
Group type: COMPARATOR
Intervention: LCT fat emulsion
Number of subjects: 20
Study 29218549 — intervention group
Group type: EXPERIMENTAL
Intervention: FreeStyle Navigator I
Number of subjects: 155
Study 27056638 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 25-50 mg/day
Number of subjects: 63
Study 27056638 — intervention group
Group type: COMPARATOR
Intervention: Alogliptin 12.5-25 mg/day
Number of subjects: 63
Study 24726046 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse Childhood Experiences (ACE) scale
Number of subjects: 364
Study 23849502 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute face-to-face educational intervention covering pain assessment and management, augmented by a leaflet and follow-up telephone call at two weeks
Number of subjects: 0
Study 23849502 — intervention group
Group type: COMPARATOR
Intervention: Usual care (wait-list control group)
Number of subjects: 0
Study 20479759 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly high-dose EPO for 3 months
Number of subjects: 32
Study 20479759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 18349391 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo-endocrine therapy (CMF chemotherapy for 6 cycles followed by goserelin)
Number of subjects: 2732
Study 18349391 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy alone (goserelin or tamoxifen)
Number of subjects: 2732
Study 18349391 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 2732
Study 18349391 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo-endocrine therapy (CMF followed by tamoxifen for 5 years)
Number of subjects: 2732
Study 16735589 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic stabilization
Number of subjects: 64
Study 16735589 — intervention group
Group type: COMPARATOR
Intervention: Open stabilization
Number of subjects: 64
Study 14646613 — intervention group
Group type: EXPERIMENTAL
Intervention: etilevodopa/carbidopa swallowed tablets
Number of subjects: 29
Study 14646613 — intervention group
Group type: EXPERIMENTAL
Intervention: etilevodopa/carbidopa tablets dissolved in water
Number of subjects: 29
Study 14646613 — intervention group
Group type: EXPERIMENTAL
Intervention: etilevodopa oral solution with carbidopa tablets
Number of subjects: 29
Study 14646613 — intervention group
Group type: COMPARATOR
Intervention: standard levodopa/carbidopa tablets
Number of subjects: 29
Study 10961868 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly PEG‐Asp dosing
Number of subjects: 144
Study 9005361 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of folic acid daily for 6 months
Number of subjects: 154
Study 9005361 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 6 months
Number of subjects: 154
Study 1289091 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation of normal diet with 3 g of omega-3 polyunsaturated fatty acids per day for 6 months (treatment group)
Number of subjects: 120
Study 1289091 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy only (control group)
Number of subjects: 120
Study 2865857 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (300 mg per day)
Number of subjects: 20
Study 2865857 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (160 mg per day)
Number of subjects: 20
Study 30861097 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person counseling
Number of subjects: 278
Study 30861097 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 278
Study 30861097 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 278
Study 30861097 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including controls)
Number of subjects: 278
Study 30861097 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person and telephone interventions
Number of subjects: 278
Study 29353523 — intervention group
Group type: EXPERIMENTAL
Intervention: Hook plate stabilization
Number of subjects: 76
Study 29353523 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopically assisted tight rope stabilization
Number of subjects: 76
Study 27100799 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy (CBGT) for 12 weeks
Number of subjects: 150
Study 27100799 — intervention group
Group type: COMPARATOR
Intervention: Waiting List (WL)
Number of subjects: 150
Study 27100799 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy (CBGT)
Number of subjects: 150
Study 25310750 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,550-nm fractional erbium glass laser (30-40 mJ)
Number of subjects: 24
Study 22844979 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg ketamine lozenge
Number of subjects: 22
Study 22844979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 20569992 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard definition of clinically significant change (PHQ-9 score ≤9 and 50% improvement)
Number of subjects: 0
Study 20569992 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliable and clinically significant change criterion c
Number of subjects: 0
Study 20569992 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic criterion
Number of subjects: 0
Study 18427312 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-endoscopic interlaminar and transforaminal technique
Number of subjects: 178
Study 18427312 — intervention group
Group type: COMPARATOR
Intervention: Conventional microsurgical technique
Number of subjects: 178
Study 15949774 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatments for low back pain
Number of subjects: 269
Study 15949774 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 269
Study 11908905 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA supplementation (1.5 g daily)
Number of subjects: 9
Study 11908905 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 9
Study 10096389 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA treatment (50 mg orally once a day for 6 months)
Number of subjects: 40
Study 10096389 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (one time a day for 6 months)
Number of subjects: 40
Study 7756393 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% LCT lipid emulsion with TPN
Number of subjects: 21
Study 7756393 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% MCT‐LCT (50‐50) lipid emulsion with TPN
Number of subjects: 21
Study 2187552 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetradecyl sulphate
Number of subjects: 55
Study 2187552 — intervention group
Group type: COMPARATOR
Intervention: Rolitetracycline
Number of subjects: 55
Study 354521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole nafate (CM)
Number of subjects: 30
Study 354521 — intervention group
Group type: COMPARATOR
Intervention: Cephalothin sodium (CP)
Number of subjects: 30
Study 354521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole nafate (CM) and Cephalothin sodium (CP)
Number of subjects: 30
Study 31992213 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-controlled ventilation (FCV)
Number of subjects: 23
Study 31992213 — intervention group
Group type: COMPARATOR
Intervention: Volume-controlled ventilation (VCV)
Number of subjects: 23
Study 30782991 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential CQ-PQ treatment (arm 1)
Number of subjects: 204
Study 30782991 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant CQ-PQ treatment (arm 2)
Number of subjects: 204
Study 28042020 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training to Enhance Early Recovery (STEER)
Number of subjects: 67
Study 28042020 — intervention group
Group type: COMPARATOR
Intervention: Usual Care plus Attention Control with Health Education (UC + AC with HE)
Number of subjects: 67
Study 24905134 — intervention group
Group type: EXPERIMENTAL
Intervention: N-butyl-2 cyanoacrylate (Histoacryl)
Number of subjects: 0
Study 24905134 — intervention group
Group type: COMPARATOR
Intervention: octyl cyanoacrylate (Dermabond)
Number of subjects: 0
Study 24905134 — intervention group
Group type: COMPARATOR
Intervention: subcuticular suture
Number of subjects: 0
Study 22908887 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART interruption
Number of subjects: 14
Study 21746799 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive women
Number of subjects: 4954
Study 21746799 — intervention group
Group type: COMPARATOR
Intervention: HIV-negative women
Number of subjects: 4954
Study 19921480 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib plus placebo
Number of subjects: 36
Study 19921480 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin plus placebo
Number of subjects: 36
Study 19921480 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib plus pregabalin
Number of subjects: 36
Study 16236418 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond Primer/Bond (SE) with 20s photo-irradiation
Number of subjects: 0
Study 16236418 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano-Bond Primer/Photo-cure adhesive (PNB) with 10s photo-irradiation
Number of subjects: 0
Study 16236418 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano-Bond Primer/Photo-cure adhesive (PNB) with 20s photo-irradiation
Number of subjects: 0
Study 16236418 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano-Bond Primer/Dual-cure adhesive (DNB)
Number of subjects: 0
Study 15061251 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous porcine secretin
Number of subjects: 22
Study 15061251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 11439794 — intervention group
Group type: COMPARATOR
Intervention: Morphine 1 mg/ml (group M)
Number of subjects: 70
Study 11439794 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 1 mg/ml plus ketamine 2 mg/ml (group K)
Number of subjects: 70
Study 11439794 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 9492501 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of buprenorphine 0.1-0.2 mg with 0.25% bupivacaine
Number of subjects: 60
Study 9492501 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of buprenorphine 0.4 mg with 0.25% bupivacaine (40 ml at 1.7 ml.h-1)
Number of subjects: 60
Study 7519114 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter removal on day 1 after surgery
Number of subjects: 59
Study 7519114 — intervention group
Group type: COMPARATOR
Intervention: Catheter removal on day 2 after surgery
Number of subjects: 59
Study 3128112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan (1 gm IV before operation)
Number of subjects: 355
Study 3128112 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (3 doses of 2 gm: first 30-60 min before operation, then 6 and 12 hours later)
Number of subjects: 355
Study 31939347 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led food exchange intervention
Number of subjects: 142
Study 31939347 — intervention group
Group type: COMPARATOR
Intervention: Routine dietary guidance and instruction (Control)
Number of subjects: 142
Study 30690679 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy-guided intraarticular shoulder injection (IAI)
Number of subjects: 30
Study 30690679 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block (SSNB)
Number of subjects: 30
Study 30690679 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 30
Study 30690679 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 28727165 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet (D)
Number of subjects: 57
Study 28727165 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (E)
Number of subjects: 57
Study 28727165 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus Exercise (DE)
Number of subjects: 57
Study 28727165 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 57
Study 24482140 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Network Analytic (SNA) measures of diffusion potential
Number of subjects: 5784
Study 24482140 — intervention group
Group type: EXPERIMENTAL
Intervention: Global network index
Number of subjects: 5784
Study 24482140 — intervention group
Group type: COMPARATOR
Intervention: Traditional analytic measures (e.g., participation rate, representativeness)
Number of subjects: 5784
Study 23497392 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health workers intervention
Number of subjects: 194
Study 23497392 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 194
Study 21714686 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein (30 mg daily)
Number of subjects: 54
Study 21714686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 19095666 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased access to emergency contraception (EC)
Number of subjects: 1490
Study 19095666 — intervention group
Group type: COMPARATOR
Intervention: Standard access to emergency contraception (EC)
Number of subjects: 1490
Study 16861075 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin composites with fiber posts
Number of subjects: 90
Study 16861075 — intervention group
Group type: COMPARATOR
Intervention: Resin composites without fiber posts
Number of subjects: 90
Study 12719053 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct laryngoscopy
Number of subjects: 51
Study 12719053 — intervention group
Group type: COMPARATOR
Intervention: Fiberoptic intubation
Number of subjects: 51
Study 12719053 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study 10788919 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsating low-air-loss surface
Number of subjects: 54
Study 10788919 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsating low-air-loss surface
Number of subjects: 54
Study 9048269 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone 0.64 mg/kg
Number of subjects: 8
Study 9048269 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone 1.25 mg/kg
Number of subjects: 8
Study 9048269 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone 0.32 mg/kg
Number of subjects: 8
Study 9048269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8322564 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal buprenorphine (4 micrograms.kg‐1 body weight)
Number of subjects: 44
Study 8322564 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular buprenorphine (4 micrograms.kg‐1 body weight)
Number of subjects: 44
Study 3524648 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaprinast (M&B 22,948, a single oral dose)
Number of subjects: 15
Study 3524648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31997490 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Number of subjects: 834
Study 31997490 — intervention group
Group type: COMPARATOR
Intervention: Control (single antiplatelet therapy)
Number of subjects: 834
Study 29502273 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose flavanol
Number of subjects: 48
Study 29502273 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose flavanol
Number of subjects: 48
Study 29502273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 29502273 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 48
Study 28622215 — intervention group
Group type: COMPARATOR
Intervention: Female-only teams
Number of subjects: 216
Study 28622215 — intervention group
Group type: COMPARATOR
Intervention: Mixed teams (individual level)
Number of subjects: 216
Study 25569324 — intervention group
Group type: COMPARATOR
Intervention: Dietary Guidelines (DG) group (n=61)
Number of subjects: 121
Study 25569324 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Guidelines + Physical Activity (DG+PA) group (n=60)
Number of subjects: 121
Study 25569324 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups pooled
Number of subjects: 121
Study 23957512 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple imputation
Number of subjects: 0
Study 23957512 — intervention group
Group type: EXPERIMENTAL
Intervention: Last observation carried forward
Number of subjects: 0
Study 23957512 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed effects model or generalized estimating equations
Number of subjects: 0
Study 21439306 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast consumption
Number of subjects: 96
Study 18067560 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthetic nurse-controlled sedation (ACS) with propofol
Number of subjects: 153
Study 18067560 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation (PCS) with propofol
Number of subjects: 153
Study 18067560 — intervention group
Group type: COMPARATOR
Intervention: No intra-operative sedation (control)
Number of subjects: 153
Study 17150053 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume mechanical ventilation
Number of subjects: 0
Study 17150053 — intervention group
Group type: COMPARATOR
Intervention: High positive end expiratory pressure
Number of subjects: 0
Study 17150053 — intervention group
Group type: COMPARATOR
Intervention: Prone positioning
Number of subjects: 0
Study 12835884 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium pamidronate (DP) 90 to 180 mg (stepwise increase) plus radiotherapy (30 Gy in ten fractions)
Number of subjects: 42
Study 12835884 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium pamidronate (DP) 180 mg (flat dose) plus radiotherapy (30 Gy in ten fractions)
Number of subjects: 42
Study 12835884 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy only (group C)
Number of subjects: 42
Study 10680442 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutrimazole 1% cream
Number of subjects: 60